Reyon Pharmaceutical Co Ltd

Reyon Pharmaceutical's capital structure is highly leveraged, with long-term debt of KRW 216.1 billion representing 98% of total equity. The company's liquidity position is weak, as evidenced by a current ratio of 0.56 and negative free cash flow of KRW 5.8 billion. Despite KRW 6.7 billion in cash and equivalents, the firm's operating cash flow of KRW 1.5 billion is insufficient to cover its debt obligations. The company's profitability metrics are sharply negative, with a return on equity of -13.45% and return on assets of -6.37%. These figures fall well below the typical performance benchmarks for the pharmaceutical industry, which usually expects positive ROE and ROA. The operating loss of KRW 30.3 billion and net loss of KRW 29.6 billion indicate significant cost overruns or revenue shortfalls relative to its cost structure. Geographic and segment exposure data is not available in the current dataset, but the firm's revenue concentration appears to be limited to its domestic South Korean market. No material international operations or product lines are disclosed in the financial snapshot. The company's growth trajectory is uncertain, with no forward-looking revenue guidance provided in the input data. The most recent actual EPS of 351.96 KRW suggests limited earnings power, and the absence of capital expenditure growth or R&D investment data makes it difficult to assess long-term innovation potential. Risk factors include high leverage and negative free cash flow, which could limit the company's ability to fund operations or invest in R&D. The risk assessment flags negative net cash after subtracting total debt as a key concern. Dilution risk is currently low, but the company's capital structure leaves it vulnerable to further equity issuance if debt financing becomes constrained. Recent events include the latest actual EPS report of 351.96 KRW, but no material filings or transcripts are included in the input data to suggest strategic shifts or operational changes.